

=> d hist

(FILE 'HOME' ENTERED AT 12:39:56 ON 14 OCT 2003)

FILE 'CAPLUS, USPATFULL, MEDLINE, EMBASE, BIOSIS' ENTERED AT 12:40:15 ON
14 OCT 2003

L1	602 S EZETIMIBE OR 163222-33-1/RN
L2	4956 S FENOFIBRATE OR 49562-28-9/RN OR FENOFIBRATE
L3	26156 S NIACIN OR 59-67-6/RN
L4	56 S L1 AND L2 AND L3
L5	2395023 S VASCULAR OR CHOLESTEROL OR ATHEROSCLERO? OR ARTERIOSCLERO? OR
L6	55 S L4 AND L5
L7	1 S L6 AND PY<2001

file caplus uspatfull medline embase biosis
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:40:15 ON 14 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:40:15 ON 14 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:40:15 ON 14 OCT 2003

FILE 'EMBASE' ENTERED AT 12:40:15 ON 14 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:40:15 ON 14 OCT 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s ezetimibe or 163222-33-1/rn
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L1 602 EZETIMIBE OR 163222-33-1/RN

=> s fenofibrate or 49562-28-9/rn or fenofibrate
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L2 4956 FENOFIBRATE OR 49562-28-9/RN OR FENOFIBRATE

=> s niacin or 59-67-6/rn
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L3 26156 NIACIN OR 59-67-6/RN

=> s l1 and l2 and l3
L4 56 L1 AND L2 AND L3

=> s vascular or cholesterol or atherosclero? or arteriosclero? or hypertension of heart
L5 2395023 VASCULAR OR CHOLESTEROL OR ATHEROSCLERO? OR ARTERIOSCLERO? OR HYPERTENSION OF HEART

=> s l4 and l5
L6 55 L4 AND L5

=> s l6 and py<2001
4 FILES SEARCHED...
L7 1 L6 AND PY<2001

=> d l7

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:633275 CAPLUS
DN 139:169333
TI Novel anticholesterol compositions and method for using same
IN Dudley, Robert; Liao, Shutsung; Song, Ching
PA USA
SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 137,695.
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003153541	A1	20030814	US 2002-174934	20020619
	WO 9922728	A1	19990514	WO 1998-US23041	19981030 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6576660	B1	20030610	US 2000-530443	20000428
	ZA 2001009793	A	20030228	ZA 2001-9793	20011128
	US 2002107233	A1	20020808	US 2002-72128	20020208
	US 2002193357	A1	20021219	US 2002-137695	20020502
PRAI	US 1997-63770P	P	19971031		
	WO 1998-US23041	W	19981030		
	US 1999-131728P	P	19990430		
	US 2000-530443	A2	20000428		
	US 2000-560236	A2	20000428		
	US 2001-267493P	P	20010208		
	US 2001-288643P	P	20010503		
	US 2001-348020P	P	20011108		
	US 2002-72128	A2	20020208		
	US 2002-137695	A2	20020502		
OS	MARPAT 139:169333				

=> d ab kwic

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN

AB Disclosed are compns., methods, combinations, and kits for treating a disorder related to elevated serum **cholesterol** concn., for example, **atherosclerosis**, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia, **cholesterol** gallstones, lipid storage diseases, obesity, and diabetes. The compns., methods, combinations, and kits of the present invention are pharmaceutical compns. comprising at least two of an LXR receptor modulator, a therapeutically effective amt. of a catechin, and/or a therapeutically effective amt. of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, a fibric acid deriv., **niacin**, a bile-acid sequestrant, an absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone compd., and an unsatd. omega-3 fatty acid.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003153541	A1	20030814	US 2002-174934	20020619
	WO 9922728	A1	19990514	WO 1998-US23041	19981030 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6576660	B1	20030610	US 2000-530443	20000428
	ZA 2001009793	A	20030228	ZA 2001-9793	20011128
	US 2002107233	A1	20020808	US 2002-72128	20020208
	US 2002193357	A1	20021219	US 2002-137695	20020502

AB Disclosed are compns., methods, combinations, and kits for treating a disorder related to elevated serum **cholesterol** concn., for example, **atherosclerosis**, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia, **cholesterol** gallstones, lipid storage diseases, obesity, and diabetes. The compns., methods, combinations, and kits of the present invention are pharmaceutical compns. . . . and/or a therapeutically effective amt. of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, a fibric acid deriv., **niacin**, a bile-acid sequestrant, an absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone compd., and an unsatd. omega-3 fatty acid.


IT **Atherosclerosis**
Hypercholesterolemia
Hypertension
Hypertriglyceridemia
(treatment of; anticholesterol compns. contg. LXR modulators and lipid regulating agents)

IT **59-67-6, Niacin**, biological studies 438-22-2D,
Androstane, derivs. 637-07-0, Clofibrate 863-03-6, Epicatechin gallate 989-51-5, Epigallocatechin gallate 11041-12-6, Cholestyramine 23288-49-5, Probucol 25812-30-0, Gemfibrozil 41859-67-0, Bezafibrate **49562-28-9, Fenofibrate** 50925-79-6, Colestipol 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 84449-90-1, Raloxifene 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin 145599-86-6, Cerivastatin **163222-33-1, Ezetimibe** 182815-44-7, Colesevelam hydrochloride 263006-09-3, TOFA 287714-41-4, Rosuvastatin 373633-12-6, Hypocholamide 475102-52-4, Hypocholaride 475207-20-6, GW3965 577786-25-5, T 1317
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticholesterol compns. contg. LXR modulators and lipid regulating agents)

=>

1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 163222-33-1 REGISTRY
 CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, [3R-[3.alpha.(S*),4.beta.]]-
 OTHER NAMES:
 CN (-)-Sch 58235
 CN Ezetimibe
 CN Sch 58235
 CN Zetia
 FS STEREOSEARCH
 MF C24 H21 F2 N O3
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CIN, DIOGENES, DRUGNL, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


105 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 105 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s fenofibrate/cn
 L2 1 FENOFIBRATE/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 49562-28-9 REGISTRY
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Ankebin
 CN Elasterin
 CN Fenobrate
 CN Fenofibrate
 CN Fenogal
 CN Fenotard
 CN Isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate
 CN LF 178

CN Lipanthyl
 CN Lipantil
 CN Lipidil
 CN Lipirex
 CN Lipoclar
 CN Lipofene.
 CN Liposit
 CN Lipsin
 CN Nolipax
 CN NSC 281319
 CN Procetofen
 CN Procetofene
 CN Procetoken
 CN Protolipan
 CN Secalip
 CN TriCor
 FS 3D CONCORD
 MF C20 H21 Cl O4
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
 CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,
 DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
 NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, ULIDAT, USAN,
 USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


692 REFERENCES IN FILE CA (1907 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 697 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s niacin/cn
 L3 1 NIACIN/CN

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 59-67-6 REGISTRY
 CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Nicotinic acid (7CI, 8CI)
 OTHER NAMES:
 CN .beta.-Pyridinecarboxylic acid
 CN 3-Carboxylpyridine
 CN 3-Carboxypyridine
 CN 3-Pyridylcarboxylic acid
 CN Akotin
 CN Apelagrin

CN Daskil
 CN Efacin
 CN Enduracin
 CN Linic
 CN Niac
 CN **Niacin**
 CN Niacor
 CN Niaspan
 CN Nicacid
 CN Nicangin
 CN Nico-Span
 CN Nicobid
 CN Nicodelmine
 CN Nicoliar
 CN Niconacid
 CN Nicosan 3
 CN Nicotinipca
 CN Nicyl
 CN NSC 169454
 CN Nyclin
 CN Pellagrin
 CN Pelonin
 CN Slo-niacin
 CN SR 4390
 CN Wampocap
 FS 3D CONCORD
 DR 123574-58-3
 MF C6 H5 N O2
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
 CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM,
 CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*,
 HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT,
 NIOSHTIC, PDLCOM*, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO,
 SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14335 REFERENCES IN FILE CA (1907 TO DATE)
 529 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 14347 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=>